A preclinical model of MPNST development demonstrated that combined cyclin-dependent kinase 4/6 (CDK4/6) and MEK inhibition sensitized MPNST to anti-PD-L1 immune checkpoint blockade (ICB) [117]. The gene discussed is MAP2K7; the disease is malignant peripheral nerve sheath tumor.